Home Bratislava Medical Journal 2023 Bratislava Medical Journal Vol.124, No.11, p.814–820, 2023

Journal info


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564


Aims and Scope
Editorial Info
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.124, No.11, p.814–820, 2023

Title: Investigation of the miR-637 and miR-523-5p as candidate biomarkers in breast cancer
Author: Ender COSKUNPINAR, Duygu Zeynep TIRYAKIOGLU, Neslihan ABACI, Mustafa TUKENMEZ, Sadrettin PENCE

Abstract: Objectives: The distinction of benign lesions from malign tumors is crucial for the diagnosis and treatment of breast cancers.
Background: The aim of this study was to investigate the use of miRNAs as plasma biomarkers for the discrimination of malign and benign breast tumors.
Methods: Whole blood samples obtained from 40 individuals in 3 groups designated as invasive ductal carcinoma group, fibroadenoma group and healthy controls were included in this study. The expression levels of 372 miRNAs were determined using RT-PCR.  
Results: The comparison of fibroadenoma group with healthy controls revealed an upregulation of thirty miRNAs and downregulation of twenty-nine miRNAs. The comparison of invasive ductal carcinoma (IDC) group with controls has shown that eight miRNAs were upregulated while eleven miRNAs were downregulated. When comparing IDC and fibroadenoma groups, 15 miRNAs were found to be upregulated, while 10 miRNAs were downregulated. Further analysis of these miRNAs aimed to determine their power in distinguishing  IDCs from fibroadenomas. Among the miRNAs analyzed, seven miRNAs have shown sufficient discriminative power, of which three miRNAs, namely miR-637, miR-523-5p and miR-490-3p, have shown a significantly high discriminative power.
Conclusions: Circulating miR-637 and miR-523-5p combination maybe used to discriminate between invasive ductal carcinomas and fibroadenomas. (Tab. 9, Fig. 4, Ref. 30).

Keywords: breast cancer; fibroadenoma; plasma; biomarker; microRNA
Published online: 24-Oct-2023
Year: 2023, Volume: 124, Issue: 11 Page From: 814, Page To: 820

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.